HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Podophyllotoxin (Condylox)

Subscribe to New Research on Podophyllotoxin

A lignan (LIGNANS) found in PODOPHYLLIN resin from the roots of PODOPHYLLUM plants. It is a potent spindle poison, toxic if taken internally, and has been used as a cathartic. It is very irritating to skin and mucous membranes, has keratolytic actions, has been used to treat warts and keratoses, and may have antineoplastic properties, as do some of its congeners and derivatives.

Also Known As:

Condylox; Wartec; Epipodophyllotoxin; Ardern Brand of Podophyllotoxin; CPH86; Canderm Brand of Podophyllotoxin; Condyline; Fides Ecopharma Brand of Podophyllotoxin; Hamilton Brand of Podophyllotoxin; Newport Brand of Podophyllotoxin; Oclassen Brand of Podophyllotoxin; Paddock Brand of Podophyllotoxin; Paladin Brand of Podophyllotoxin; Podocon-25; Podofilm; Podofilox; Podophyllotoxin, (5R-(5 alpha,5a alpha,8a alpha,9 alpha))-Isomer; Podophyllotoxin, (5R-(5 alpha,5a alpha,8a alpha,9 beta))-Isomer; Podophyllotoxin, (5R-(5 alpha,5a alpha,8a beta,9 alpha))-Isomer; Podophyllotoxin, (5R-(5 alpha,5a beta,8a alpha,9 beta))-Isomer; Stiefel Brand of Podophyllotoxin; Warticon; Wolff Brand of Podophyllotoxin; Yamanouchi Brand of Podophyllotoxin; Furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5aH)-one, 5,8,8a,9-tetrahydro-9-hydroxy-5-(3,4,5-trimethoxyphenyl)-, (5R-(5alpha,5abeta,8aalpha,9alpha))-

Networked: 391 relevant articles (36 outcomes, 56 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Kamal, Ahmed: 9 articles (11/2015 - 11/2003)
2.	Chen, Hong: 5 articles (03/2015 - 02/2010)
3.	Cao, Bo: 4 articles (03/2015 - 02/2010)
4.	Suresh, Paidakula: 4 articles (09/2013 - 12/2010)
5.	Bailly, Christian: 4 articles (04/2012 - 02/2006)
6.	Behmanesh, Mehrdad: 3 articles (01/2015 - 03/2012)
7.	Srinivasa Reddy, T: 3 articles (10/2014 - 09/2013)
8.	Shankaraiah, Nagula: 3 articles (10/2014 - 09/2013)
9.	Qi, She-Ning: 3 articles (06/2013 - 07/2007)
10.	Li, Guo-feng: 3 articles (06/2011 - 05/2007)

Related Diseases

1.	Warts (Wart) 08/01/2003 - "When subjects defaulting from follow up were assumed not to have been cured odds of remission of all warts were significantly increased for podophyllotoxin solution (OR 1.92, 95% CI 1.13 to 3.27), but not for podophyllotoxin cream (OR 1.17, 95% CI 0.69 to 2.00). " 08/01/2003 - "When subjects defaulting from follow up were assumed to have been cured odds of remission of all warts were also significantly increased both for podophyllotoxin solution (OR 3.04, 95% CI 1.68 to 5.49) and for podophyllotoxin cream (OR 2.46, 95% CI 1.38 to 4.40). " 04/01/1994 - "When analysing the debulking potential of podophyllotoxin, it appeared that 0.25% podophyllotoxin eradicated 184 of originally 217 warts (85%); the corresponding figure for 0.50% podophyllotoxin was as high as 130 of 135 lesions (96%). " 05/01/1990 - "Podofilox 0.5% solution is effective in treating penile warts and is well tolerated in a self-administered regimen. " 01/01/1998 - "To determine the safety and efficacy of a new gel formulation of podofilox in the treatment of anogenital warts. "
2.	Condylomata Acuminata (Genital Wart) 02/01/1995 - "In the therapeutic arsenal for the treatment of condylomata, podophyllotoxin 0.5% is a first line treatment for condylomata acuminata of the genital mucous membranes." 10/01/1990 - "Thus, 0.5% podofilox solution appears to be an effective treatment for condylomata acuminata, with acceptable side effects that are local and temporary." 12/01/1990 - "In conclusion podophyllotoxin 0.5% appeared to be safe and effective for the self treatment of genital warts." 01/01/1993 - "The purpose of this comparative open study was to determine the clinical efficacy of 0.3% podophyllotoxin both in 70% ethanolic solution and cream preparations on genital warts. " 12/01/1995 - "To evaluate the clinical efficacy of a 0.15% and a 0.3% cream formulation of podophyllotoxin in comparison with the 0.5% solution in the treatment of condylomata acuminata and to compare the treatment modalities regarding side effects. "
3.	Neoplasms (Cancer) 10/01/2012 - "Adva-27a, a novel podophyllotoxin derivative found to be effective against multidrug resistant human cancer cells." 03/01/2010 - "In order to overcome these limitations, it is essential to search new podophyllotoxin analogues with improved anticancer activity and fewer side effects to gain the maximum benefits for the cancer patients. " 11/01/2015 - "In our previous studies 4β-cinnamido linked podophyllotoxin conjugates were synthesized and evaluated for their cytotoxic activity in a panel of five human cancer cell lines and the new molecules like 17a and 17f were considered as potential leads. " 03/01/2015 - "In this study, we aimed to investigate CIP-36, a novel podophyllotoxin derivative, for its inhibitory effects on human cancer cells from multiple sources, particularly cells with MDR in vitro. " 03/21/2014 - "To extend our prior studies in this research area, we synthesized a new generation of spin-labeled podophyllotoxin analogs via isocyanide multicomponent reactions and evaluated their cytotoxicity against four human cancer cell lines (A-549, DU-145, KB and KBvin). "
4.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 12/01/1995 - "Epipodophyllotoxin-related acute myeloid leukemia: a study of 35 cases." 01/01/1982 - "Clinical and cell kinetic studies of the effects of the epipodophyllotoxin VP16-213 during therapy of refractory acute nonlymphocytic leukemia." 10/01/1998 - "High cumulative epipodophyllotoxin dosages are reported to be associated with an elevated risk for secondary acute myeloid leukemia (s-AML). " 03/01/1997 - "Treatment of children with epipodophyllotoxin-induced secondary acute myeloid leukemia." 10/01/1995 - "The risk for induction of epipodophyllotoxin-related acute myeloid leukemia (AML) depends largely on the schedule of drug administration and, to a lesser degree, the cumulative dose. "
5.	Leukemia 06/01/2015 - "Cytotoxic activity of podophyllotoxin and selected leaf extracts of Juniperus sp. against a set of leukemia cell lines was demonstrated." 06/01/2015 - "Podophyllotoxin IC50 cytotoxicity values against J45.01 and CEM/C1 leukemia cell lines were 0.0040 and 0.0286 µg/mL, respectively. " 01/01/2014 - "Compound A398, a novel podophyllotoxin analogue: cytotoxicity and induction of apoptosis in human leukemia cells." 12/01/2010 - "Whatever the model, we failed to evidence a role for the radiation dose to active bone marrow in the risk of later leukemia, myelodysplasia, or myeloproliferative syndrome, when adjusting for epipodophyllotoxin and anthracycline doses. " 02/01/2010 - "Reversal of mdr1-mediated multidrug resistance in human leukemia cells by a new spin-labeled derivative of podophyllotoxin."

Related Drugs and Biologics

1.	Podophyllin
2.	imiquimod (Aldara)
3.	Etoposide (VP 16)
4.	Teniposide (VM 26)
5.	Thiotepa (Triethylenethiophosphoramide)
6.	etoposide phosphate (Etopophos)
7.	Methotrexate (Mexate)
8.	Ethanol (Ethyl Alcohol)
9.	Salicylic Acid (2 Hydroxybenzoic Acid)
10.	Granulocyte Colony-Stimulating Factor (G-CSF)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Laser Therapy (Surgery, Laser)
3.	Remission Induction
4.	Solid-State Lasers
5.	Self Medication